-

12:52:25 PM

ALLO Stock News

ALLO - Allogene Therapeutics Inc

09/27/23 9:09 AM

Nasdaq : ALLO

Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Spotlight on Novel, Targeted Technologies to Enhance Engraftment, Expansion and Persistence of AlloCAR T™ Cells Demonstration of Dagger™ Technology to Engineer CAR T cells to Selectively Eliminate CD70 Positive, Allo-Reactive Host Immune Cells Evaluation of Cloak™ Technology to Engineer Allogeneic

RHEA-AI

neutral

09/05/23 8:30 AM

Nasdaq : ALLO

Allogene Therapeutics Announces Participation in September Investor Conference

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in an upcoming investor

RHEA-AI

neutral

09/05/23 7:00 AM

Nasdaq : ALLO

Cantor Fitzgerald Bolsters Healthcare and Biotechnology Equity Research Team with Addition of Josh Schimmer, M.D., and Eric Schmidt, Ph.D.

Cantor Fitzgerald, L.P., a leading global financial services firm, today announced the addition of Josh Schimmer, M.D., and Eric Schmidt, Ph.D., to its Healthcare and Biotechnology Research platform. Pascal Bandelier, Senior Managing...

RHEA-AI

positive

08/14/23 8:30 AM

Nasdaq : ALLO

management

Allogene Therapeutics Appoints Earl Douglas as General Counsel

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that Earl Douglas has been appointed as General

RHEA-AI

neutral

08/02/23 4:02 PM

Nasdaq : ALLO

earnings

Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update

Presented Long-Term Data for an Allogeneic CD19 CAR T Product Candidate in Relapsed/Refractory Large B Cell Lymphoma (LBCL) at the American Society of Clinical Oncology (ASCO) Annual Meeting and International Conference on Malignant Lymphoma (ICML) Lugano ALLO-501/501A Demonstrated Rates of Durable

RHEA-AI

neutral

07/26/23 8:30 AM

Nasdaq : ALLO

conferencesearnings

Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today

RHEA-AI

neutral

06/15/23 9:30 AM

Nasdaq : ALLO

clinical trial

Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano

Presentation Includes Data on All 33 CAR T-Naïve Patients Treated with the Alloy™ Manufactured Material and Recaps Data on 12 Large B Cell Lymphoma Patients Treated with Phase 2 Dose Regimen Results Indicate an Off-the-Shelf Allogeneic CAR T Can Potentially Deliver Durable Complete Responses

RHEA-AI

neutral

06/14/23 8:00 AM

Nasdaq : ALLO

Allogene Therapeutics Announces Departure of Chief Financial Officer

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, announced that its Chief Financial Officer, Eric T. Schmidt, Ph.D.,

RHEA-AI

neutral

06/09/23 6:25 PM

Nasdaq : ALLO

clinical trial

Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano

Long-Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrates Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous Therapies Presentation Recaps 12 Patients Treated with Phase 2 Dose Regimen and Includes Additional Data on All 33 CAR T

RHEA-AI

neutral

06/03/23 9:00 AM

Nasdaq : ALLO

clinical trial

Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting

Long Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous Therapies Presentation Focused on Patients (n=12) Treated with Phase 2 Regimen 67% Overall Response Rate (ORR) and 58%

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

ALLO Data

IndustryResearch and Development in Biotechnology
Websiteallogene.com
Security nameAllogene Therapeutics Inc
SectorProfessional, Scientific, and Technical Services
Tags
- Health Technology
- Biotechnology

About Allogene Therapeutics Inc

allogene therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor t-cell (car t) therapy directed at blood cancers and solid tumors. founded and led by former kite pharma executives who bring unrivaled clinical development acumen in cell therapy, allogene is well-positioned to further the potential of allogeneic cell therapy for patients. allogeneic car t therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. this approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for car t treatment. the allogene portfolio includes 16 pre-clinical t cell therapy assets and ucart19, an allogeneic car t therapy currently in phase 1 development for the treatment of acute lymphoblastic leukemia (all). through its notable partnerships, allogene le